Drug Discovery@nature.com 6 July 2012

TABLE OF CONTENTS 6 July 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement A research group at Karolinska Institutet have unlocked the secrets of the skin’s perviousness! This will hopefully enable the widespread administration of drugs though the skin instead of via pills or injections. The Human Skin Barrier Open Access I Iwai et al ¦ doi:10.1038/jid.2012.43 Published in The Journal of Investigative Dermatology   News Top Weight-loss drug wins US approval doi:10.1038/nature.2012.10923 Obesity treatment shows promise for patients with diabetes despite concerns that it could cause heart complications. Full Text Deal watch: Epizyme–Celgene deal signals interest in new class of epigenetic drugs doi:10.1038/nrd3772 Partnership will focus on the discovery, development and commercialization of inhibitors of histone methyltransferases for genetically defined cancers. Full Text An Audience With: Alan Trounson doi:10.1038/nrd3769 The President of the California Institute for Regenerative Medicine discusses his plans to get more stem cell therapeutics into clinical trials. Full Text Informed consent: A broken contract doi:10.1038/486312a As researchers find more uses for data, informed consent has become a source of confusion. Something has to change. Full Text Analysis Top Liquid biopsy doi:10.1038/scibx.2012.668 A Cancer Research UK team has developed a diagnostic platform that uses tumor-derived circulating DNA to noninvasively monitor a patient's response to therapy. Full Text FDA advisory committee meeting outcomes doi:10.1038/nrd3747 This analysis of the outcomes of advisory committee meetings held by the US FDA over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions. Full Text Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text Research Highlights Top Cancer: Of targets and anti-targets doi:10.1038/nrd3781 Polypharmacology is difficult to predict. Now, researchers have taken a systems pharmacology approach, identifying targets and anti-targets for the rational design of drugs with an optimized polypharmacological profile. Full Text Metabolic disorders: Heart microRNA provides new route to metabolic control doi:10.1038/nrd3779 Researchers have discovered a novel role of the heart in systemic metabolic control and suggest that miR-208a inhibition may have applications in the treatment of metabolic disorders. Full Text Anticancer drugs: Antipsychotic to anticancer agent? doi:10.1038/nrd3783 A new study has screened for compounds that selectively differentiate cancer stem cell-like cells and has identified dopamine receptor antagonists as promising candidates. Full Text Research & Reviews Top Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars doi:10.1038/nrd3746 This review looks at the analytical technologies available to assess biosimilars, focusing on the assessment of post-translational modifications, three-dimensional structures and protein aggregation. Full Text Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma doi:10.1038/nrd3745 This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities. Full Text IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells doi:10.1038/nm.2817 The identification of an IL-23–responsive CD4−CD8− T cell population points to new therapeutic targets for this group of rheumatic disorders. Full Text A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis doi:10.1038/nm.2826 Researchers have discovered a new axis that mediates the pathogenic progression of endometriosis, and suggest that the antibody to TNF-α etanercept might offer a therapy. Full Text Drug Discovery JOBS of the week Drug and biomarkers delivery using cell-penetrating peptides TU-Darmstadt PhD studentship on large-scale quantum chemistry methods applied to drug discovery University of Southampton - Chemistry Institute Research Scientist � Drug Metabolism MD Anderson Cancer Center Postdoctoral Researcher Marine Natural Products in Drug Discovery NUI Galway Ireland Research Associate, Drug Metabolism Pharmacokinetics Otsuka More Science jobs from Drug Discovery EVENT Biomarkers in Drug Discovery & Development 10.-11.09.12 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.